NCT03853993View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

PHASE3CompletedINTERVENTIONAL

Enrollment

2,380

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

August 17, 2018

Study Completion Date

October 8, 2018

Conditions

Seasonal Influenza

Interventions

BIOLOGICAL

Quadrivalent influenza vaccine

Received single dose QIV (15µg/0.5ml)

BIOLOGICAL

Trivalent influenza vaccine (contains B/Victoria strain)

Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)

BIOLOGICAL

Trivalent influenza vaccine (contains B/Yamagata strain)

Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)

Trial Locations (2)

221300

Pizhou Center for Disease Control and Prevention, Pizhou

222200

Guanyun Center for Disease Control and Prevention, Lianyungang

All Listed Sponsors

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT03853993 - Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml) | Biotech Hunter | Biotech Hunter